Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma-Reference-Cited by-全球学者库

Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma

Published:2011-09-01 Issue:9 Volume:6 Page:e23621
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Zeng Zhen,Shi Feng,Zhou Lin,Zhang Min-Na,Chen Yan,Chang Xiu-Juan,Lu Yin-Ying,Bai Wen-Lin,Qu Jian-Hui,Wang Chun-Ping,Wang Hong,Lou Min,Wang Fu-Sheng,Lv Ji-Yun,Yang Yong-Ping

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference43 articles.

1. Multidisciplinary management of hepatocellular carcinoma.;WS Rilling;J Vasc Interv Radiol,2002

2. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?;R Lencioni;Oncologist,2010

3. The global health burden of infection-associated cancers in the year 2002.;DM Parkin;Int J Cancer,2006

4. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival.;JM Llovet;Hepatology,2003

5. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma.;M Samuel;Cochrane Database Syst Rev,2009

Cited by 156 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The immune response of hepatocellular carcinoma after locoregional and systemic therapies: The available combination option for immunotherapy;BioScience Trends;2023-12-31

2. The current status and future of PD-L1 in liver cancer;Frontiers in Immunology;2023-12-12

3. The programed death‐1/programed death ligand‐1 axis and its potential as a therapeutic target for virus‐associated tumours;Reviews in Medical Virology;2023-10-31

4. A Comparative Study of Antitumor Immunity Induced by Radiofrequency Microwave and Cryoablation in Hepatocellular Carcinoma;Applied Biochemistry and Biotechnology;2023-10-27

5. Combination Therapy of Immune Checkpoint Inhibitors with Locoregional Therapy for Hepatocellular Carcinoma;Cancers;2023-10-20